



Hollis-Eden Pharmaceuticals, Inc.
4445 Eastgate Mall, Suite 400
San Diego, CA 92121
Telephone: 858 587 9333
Fax: 858 558 6470

JKW

1615



HOLLISEDEN
PHARMACEUTICALS
Serving Humanity

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY "FIRST-CLASS MAIL"

Attorney Docket No. : 202.8
Serial No. : 10/087,929
Applicant(s) : Clarence N. Ahlem, et al.
For : Blood Cell Deficiency Treatment Method
Attorney : Daryl D. Muenchau, Reg. No. 36,616
Date of Deposit : August 13, 2004

I hereby certify that the accompanying

Transmittal (in duplicate); Information Disclosure Statement (Form PTO-1449 (34 references); and Return Postage Prepaid Postcard

are being deposited with the United States Postal Service "First-Class Mail" service on the date indicated above and are addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Candace Pinelli
Candace Pinelli



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.
Application No. : 10/087,929
Filed : March 1, 2002
Title : Blood Cell Deficiency Treatment Method
Examiner : James M. Spear
TC/A.U. : 1615

Docket No. : 202.8
Customer No. : 26551
Confirmation No. : 7989

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT TRANSMITTAL

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing 34 references. A copy of foreign patent documents and other documents are enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b). Please charge any fees due or credit any overpayments to **Deposit Account No. 501536**. A duplicate copy of this sheet is enclosed.

Please direct all correspondence to **Customer No. 26,551**.

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated:

Aug. 13, 2004

By:

Daryl D. Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.
Application No. : 10/087,929
Filed : March 1, 2002
Title : Blood Cell Deficiency Treatment Method
Examiner : James M. Spear
TC/A.U. : 1615

Docket No. : 202.8
Customer No. : 26551
Confirmation No. : 7989

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT TRANSMITTAL

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing 34 references. A copy of foreign patent documents and other documents are enclosed. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b). Please charge any fees due or credit any overpayments to **Deposit Account No. 501536**. A duplicate copy of this sheet is enclosed.

Please direct all correspondence to **Customer No. 26,551**.

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.


Dated: Aug. 13, 2004

By: Daryl D. Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.8APPLICATION NO.
10/087,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY

APPLICANT
Ahlem, et al.FILING DATE
3/1/02GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
.	2002/0019376 A1	Savage et al.			
	2004/0097406 A1	Ahlem et al.			
.	2003/0113284 A1	Dalko et al.			
	2002/0091278 A1	Savage et al.			
	2003/0060425 A1	Ahlem et al.			
	2004/0116359 A1	Ahlem et al.			
	2004/0060425 A1	Ahlem et al.			
	2002/0187973 A1	Labrie			
	2004/0043973 A1	Ahlem et al.			
	2004/0082556 A1	Labrie et al.			
	2003/0083231 A1	Ahlem et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 576 915 B1	01/05/94	Europe				
	WO 99/08684	08/17/98	PCT				
	WO 97/41867	11/13/97	PCT				
	EP 0 576 914 A2	01/05/94	Europe				


EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.8	APPLICATION NO. 10/087,929
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Ahlem, et al.	
		FILING DATE 3/1/02	GROUP 1615

USE SEVERAL SHEETS IF NECESSARY



EXAMINER INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Wheeler, O., et al, "Steroid derivatives of cysteamine and cysteine", <i>Canadian J of Chem</i> , Vol 47, pp 160-62 (1969)
	Kondziolka, D., et al, "Beneficial effects of the radioprotectant 21-aminosteroid U-74389G in a radiosurgery rat malignant glioma model", <i>Int. J. Rad. Onc. Biol. Phys.</i> , Vol 44 (1), pp. 179-84 (1999)
	Evens, R., et al, "Androgens and erythropoiesis", <i>J. Clin. Pharm.</i> , pp. 94-101 (1974)
	Sigg, H., et al, "Helvetica Chimica ACTA", Vol. 39 (6), pp. 1507 - 1525 (1956)
	Mulder, et al., "Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men", <i>J. of Infectious Diseases</i> , 165, pp. 413-18 (1992)
	Clerici, et al., "A possible role for the cortisol/anticortisol imbalance in the progression of human immunodeficiency virus", <i>Psychoneuroendocrinology</i> 22 (Suppl 1), pp S27-S31 (1997)
	Rasmussen, K., et al, "Effects of dehydroepiandrosterone in immunosuppressed rats infected with cryptosporidium parvum", <i>J. Parasitol</i> , Vol. 79 (3), pp. 364-70 (1993)
	Loria, et al., "Androstenediol regulates systemic resistance against lethal infections in mice", <i>archives of Virology</i> , 127, pp. 105-15 (1992)
	Gidari, A., et al, "Cyproterone-mediated stimulation of δ -aminolevulinic acid synthetase in chick embryo liver cells", <i>Endocrinology</i> , 99, pp. 130-36 (1976)
	Morrow, D., et al, "The synthesis of 17 β -amino-17-isoprogesterone", <i>J Org Chem</i> , pp 579-87 (1965)
	Goldman, A., et al, "Inhibitors of human placental C ₁₉ and C ₂₁ 3 β -hydroxysteroid dehydrogenases", <i>Biochimica et Biophysica Acta</i> , 315, pp. 233-49 (1973)
	Padgett, et al., "In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstenediol", <i>J. of Immunology</i> , 153, pp. 1544-52 (1994)
	Moog, et al., "Oxysterols, but not cholesterol, inhibit human immunodeficiency virus replication in vitro", <i>Antiviral Chememistry & Chemotherapy</i> , pp. 9, pp. 491-96 (1998)
	Xia, P, et al, "Anti-AIDS agents. Part 36: 17-carboxylated steroids as potential anti-HIV agents", <i>Bioorganic & Medicinal Chem</i> , 7, pp. 1907-11 (1999)
	Daigle, J., et al., "Androstenediol antagonizes herpes simplex virus type 1-induced encephalitis through the augmentation of type 1 IFN production", <i>The J of Immunology</i> , pp. 3060 - 3066 (1998)
	Lafaye, P. et al., "The 7 α -hydroxysteroids produced in human tonsils enhance the immune response to tetanus toxoid and Bordetella pertussis antigens", <i>Biochimica et Biophysica Acta</i> , 1472, pp. 222 - 31 (1999)
	Faredin, I., et al., "Transformation in vitro of [4- ¹⁴ C]-dehydroepiandrosterone into 7-oxygenated derivatives by normal human male and female skin tissue", <i>The J of Investigative Dermatology</i> , Vol. 52, No. 4, pp. 357 - 61 (1969)
	Davis, A., et al, "Stereocontrolled synthesis of cholic acid derivatives with N-protected 7 β -and/or 12 β -amino substituents", <i>Tetrahedron Letters</i> , Vol 33, No. 35, pp. 5111-12 (1992)
	Davis, M., et al, "Steroid amines. Part IV. 3,17-diaminoandrostane derivatives", <i>J Chem. Soc</i> , 11, pp. 1045 - 52 (1967)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	